AlzeCure Pharma has announced that a response letter has been published related to the previously published scientific article on Alzstatin and the lead drug candidate in the project, ACD680.
The response letter, titled "Response to the Letter to the Editor on “γ-Secretase modulation and plaque regression in Alzheimer’s disease”, has been published online in The Journal of Pharmacology and Experimental Therapeutics (JPET).
The published post is a response to a post published by Ghosh et al. following the recently published scientific article regarding Alzstatin.
Substances in the Alzstatin project, named gamma-secretase modulators, reduce the production of amyloid-beta 42 protein (Aβ42), which is the building block of the amyloid plaques found in the brains of Alzheimer's patients.
The production of shorter Aβ peptides, such as Aβ37 and Aβ38, also increases.
These have been reported to have protective effects and, among other things, can reduce the aggregation of Aβ42.
The results also show that gamma-secretase modulators can stop the growth and reduce the amount of amyloid plaques in the brain of animal models.
"The post aims to clarify the possibilities in the field and demonstrate the unique properties of this class of substances for the treatment of patients with Alzheimer's disease," said Gunnar Nordvall, Director of Medicinal Chemistry at AlzeCure Pharma.
”ACD680, the lead drug candidate in the Alzstatin project, is a highly potent small-molecule gamma-secretase modulator," said Martin Jönsson, CEO of AlzeCure Pharma.
"Like Roche's compound, it is currently undergoing Phase II clinical trials and has the advantage of being taken as a tablet, is cost-effective and optimised to cross the blood-brain barrier."
“In addition, ACD680 is a disease-modifying and preventive treatment with a larger potential patient population than the antibody treatments that have recently reached the market.”